People · Operator
Named in public records as an officer, director or promoter · active 2012–2020 · Pharma, Computers
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| March Therapeutics, Inc. | — | Pharma | Series B | $23.0M | $289.6M | 2020 |
| MessageMind, LLC | — | Computers | Seed | $3.4M | $139.8M | 2012 |
Daniel I. DeWolf at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel I. DeWolf on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Clare Ozawa | 1 | 8 |
| Jeong Seuk Kang | 1 | 4 |
| Fahim Farzadfard | 1 | 2 |
| Manish Sood | 1 | 2 |
| Habib I. Haddad | 1 | 1 |
| Antonio I. Alvarez | 1 | 1 |
| Adam I. Mullinax | 1 | 1 |
| Alain I. Oberrotman | 1 | 1 |
| Al I. Lakhani | 1 | 1 |
| Joseph I. Kaidanow | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.